Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-01
DOI
10.1038/s41379-019-0312-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma
- (2018) Ana Banito et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT)
- (2018) Isidro Machado et al. VIRCHOWS ARCHIV
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas
- (2017) Maria Antonella Laginestra et al. MOLECULAR CANCER RESEARCH
- Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas
- (2017) Christian Spurny et al. PEDIATRIC BLOOD & CANCER
- Emerging targets in cancer immunotherapy
- (2017) Samantha Burugu et al. SEMINARS IN CANCER BIOLOGY
- Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
- (2017) Paweł Krawczyk et al. Oncotarget
- Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
- (2017) Haipeng Xu et al. Scientific Reports
- Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas
- (2017) Diego Antonio Costa Arantes et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis
- (2017) Yi Que et al. Journal of Cancer
- Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
- (2017) Gino K. In et al. Therapeutic Advances in Medical Oncology
- PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas
- (2017) François Bertucci et al. OncoImmunology
- PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
- (2017) Jan Budczies et al. OncoImmunology
- PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
- (2017) Melanie Boxberg et al. OncoImmunology
- Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
- (2016) Chan Kim et al. BMC CANCER
- Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
- (2016) Yayan T. Sundara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
- (2016) Sandra P. D'Angelo et al. CLINICAL CANCER RESEARCH
- CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma
- (2016) Qinglin Han et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
- (2016) Christopher W. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas
- (2016) Semra Paydas et al. MEDICAL ONCOLOGY
- Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
- (2016) Marie Kostine et al. MODERN PATHOLOGY
- Three-year Follow up of GMCSF/bi-shRNA furin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
- (2016) Maurizio Ghisoli et al. MOLECULAR THERAPY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Advances in sarcoma diagnostics and treatment
- (2016) Amanda R. Dancsok et al. Oncotarget
- Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
- (2016) Theodore S. Nowicki et al. Cancer Immunology Research
- Description of the immune microenvironment of chondrosarcoma and contribution to progression
- (2016) François A. Simard et al. OncoImmunology
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
- (2016) Yuki Honda et al. OncoImmunology
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
- (2016) Pratistha Koirala et al. Scientific Reports
- Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors
- (2015) Elizabeth G. Demicco et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
- (2015) M. S. Merchant et al. CLINICAL CANCER RESEARCH
- Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
- (2015) Sandra P. D’Angelo et al. HUMAN PATHOLOGY
- Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
- (2015) Michael S. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- (2015) Antonio Calles et al. Journal of Thoracic Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiotherapy and Immunogenic Cell Death
- (2015) Encouse B. Golden et al. SEMINARS IN RADIATION ONCOLOGY
- PD-L1 and CD8+PD1+lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy
- (2015) Ferdousi Chowdhury et al. OncoImmunology
- CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study
- (2015) Benedikt Fritzsching et al. OncoImmunology
- Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
- (2015) Sofia R. Gameiro et al. Oncotarget
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
- (2014) P. F. Robbins et al. CLINICAL CANCER RESEARCH
- First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
- (2014) R.J. Young et al. EUROPEAN JOURNAL OF CANCER
- NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
- (2014) Makoto Endo et al. MODERN PATHOLOGY
- Programmed Cell Death Ligand 1 Expression in Osteosarcoma
- (2014) J. K. Shen et al. Cancer Immunology Research
- New drugs and clinical trial design in advanced sarcoma: have we made any progress?
- (2013) Anastasia Constantinidou et al. Future Oncology
- Activating transcription factor 2 in mesenchymal tumors
- (2013) Makoto Endo et al. HUMAN PATHOLOGY
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
- (2012) M. Leahy et al. ANNALS OF ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data
- (2012) Tom Treasure et al. BMJ Open
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase 1 and 2 in mesenchymal tumors
- (2011) Marina Pacheco et al. MODERN PATHOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays
- (2009) Hongwei Cheng et al. HUMAN PATHOLOGY
- Antibody Elution Method for Multiple Immunohistochemistry on Primary Antibodies Raised in the Same Species and of the Same Subtype
- (2009) Daniel Pirici et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now